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Telomere lengtha b s t r a c t
Cord blood (CB) leukocytes have inherent telomere length (TL) variation, and CB hematopoietic stem cells
(HSC) can maintain high telomerase levels preventing telomere attrition in vitro. We evaluated TL changes in
13 adult double-unit CB transplant (CBT) recipients. In the 26 units, we observed a marked variation in CB TL
at thaw (median, 9.99 kilobases [kb]; range, 6.85 to 13.5). All 13 patients engrafted. Of 11 engrafting with 1
unit, there was no correlation between unit dominance and TL (mean dominant unit TL, 8.84 kb  1.76; mean
nonengrafting unit TL, 10.3 kb  1.81; P ¼ .77). Serial measurements of TL up to 1 year after CBT demonstrated
an overall mean 3.04 kb  .16 TL decrease with only 1 patient exhibiting telomere maintenance. In summary,
initial TL does not predict CB unit dominance. Moreover, our analysis suggests neonatal hematopoiesis makes
a transition to an HSC characterized by changes in average TL and potentially low telomerase asymmetric cell
division in adult CBT recipients. Further investigation of alterations in telomere length and its clinical im-
plications after transplantation of this observation are indicated.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION there is an inherent biological variation at birth. We have
Cord blood (CB) is an alternative source of allogeneic
hematopoietic stem cells (HSC) for the transplantation of
patients lacking suitable HLA-matched adult donors.
Although CB transplantation (CBT) has the advantage of
reduced stringency of requiredHLAmatch, it is limited by the
low progenitor cell dose, resulting in impaired engraftment
and restricting the application of CBT in larger children and
adults. One strategy to extend transplantation access in adult
patients is to combine 2 units in a double-unit graft [1].
Intriguingly, a single unit mediates sustained donor hema-
topoiesis in the majority of patients. However, the mecha-
nisms of unit dominance have not been fully elucidated.
Furthermore, although healthy long-term survivors of CBT
are documented, the long-term effects of transplanting a
limited number of HSC from a CB unit into adult recipients
have not been fully established.
It is known that CB progenitors have a signiﬁcantly
higher replicative potential than adult HSC [2], althoughpreviously shown that CB demonstrates maintenance of
telomere length (TL) in vitro due to persisting levels of
telomerase activity for 4 to 5 months [3]. The effect of
replicative stress in vivo on TL, however, is unknown. We,
therefore, investigated the extent of TL variability in
clinical CB units, the inﬂuence of TL upon unit dominance
after CBT, and the effect of the in vivo microenvironment
on the degree of neonatal TL changes during the ﬁrst
post-transplantation year in adult double-unit CBT
recipients.
STUDY DESIGN
Thirteen patients with high-risk hematologic malignancies under-
went transplantation with 4 to 6 of 6 HLA-A, -B antigen, -DRB1
allele-matched unrelated donor double-unit CB grafts after myeloablative
or nonmyeloablative conditioning, as previously described [4-6]. All
patients provided informed consent for transplantation in accordance
with the Declaration of Helsinki and signed institutional review
boardeapproved consent for the laboratory analysis of each CB unit and
serial peripheral blood samples. Each CB unit was analyzed on the same
day as clinical transplantation. Mononuclear cells (MNCs) were isolated
from each unit and from peripheral blood at days 28, 100, 180, and 1 year
after CBT by density gradient separation with Ficoll-Hypaque. DNA was
then isolated from MNC pellets and quantiﬁed using a BioTek Synergy H1
Hybrid Multi-Mode Microplate Reader (BioTek, Winooski, VT). Southern
Blot was performed using the Roche TeloTAGGG Telomere Length Assay
(Roche Diagnostics GmBH, Mannheim, Germany) per the manufacturer’s
instructions. Clinical engraftment was evaluated after transplantation
Figure 1. Bar chart to show the TL in kb for each CB unit of 13 patients from the day of transplantation (day 0) to last follow-up. Patients were analyzed up to 1 year
after transplantation or death (3 patients died before 1 year). The unit with the higher infused viable CD34þ dose per kilogram recipient body weight is indicated with
a þ sign above the unit on day 0. (A) In 9 patients demonstrating complete single-unit dominance from 28 days after CBT, the unit responsible for sustained donor
hematopoiesis is indicated in greenwhereas nonengrafting units are shown in red. Only 1 patient with complete unit dominance demonstrated TL maintenance after
transplantation with a mean percentage TL gain of 11.5% (indicated with the asterisk). (B) Unit TL in 2 patients who displayed initial mixed chimerism but ultimate
unit dominance (indicated in green). The proportions represent the contribution of each unit at that time point with the grey indicating a transient contribution of
host hematopoiesis. (C) TL in 2 patients with complete donor engraftment but persistent mixed chimerism at 1 year after CBT. Given the units coengrafted and clear
unit dominance could not assigned, they are indicated in light and dark blue.
B. Ashbridge et al. / Biol Blood Marrow Transplant 21 (2015) 1315e1336 1335using quantitative PCR for informative short tandem repeat regions that
distinguished each donor and the recipient [7]. Two-sided t-tests were
utilized to determine potential correlations between TL and unit
dominance.RESULTS
Twenty-six CB units were used in the transplantation for
13 patients (median age, 52 years; range, 23 to 61). We
B. Ashbridge et al. / Biol Blood Marrow Transplant 21 (2015) 1315e13361336observed a marked variation in CB TL at thaw: median 9.99
kilobases (kb)  1.86 (range, 6.85 to 13.5). Day 0 values are
shown in Figure 1. The median infused total nucleated cell
dosewas 2.9 107/kg (range, 2.0 to 4.4) in the larger unit and
2.0  107/kg (range, 1.7 to 2.7) in the smaller unit. All 13
patients engrafted at a median of 22 days (range, 15 to 28) in
9 myeloablative recipients and 9 to 13 days after CBT in 4
nonmyeloablative recipients.
One CB unit mediated donor hematopoiesis in 11 patients
(dominant unit in green, Figure 1A,B) whereas 2 patients
showed mixed chimerism up to 1 year later (Figure 1C). In
the 11 patients with unit dominance, therewas no signiﬁcant
association between the infused total nucleated cell dose,
viable CD34þ cell dose, or CD3þ cell dose, nor the percentage
of viable CD34þ cells post-thaw of each unit and unit
dominance (all P ¼ not signiﬁcant). Speciﬁcally, the infused
viable CD34þ cell dose of the dominant unit was .88 105/kg
(range, .44 to 3.46) and that of the nondominant unit was
1.25  105/kg (range, .22 to 3.14). Of these 11 patients, 5
patients engrafted with the unit that had the longer TL
(median, 11.0 kb; range, 9.93 to 13.2), whereas 6 engrafted
with the shorter TL unit (median, 9.55 kb; range, 6.8 to 10.2),
P ¼ not signiﬁcant. Overall, there was no relationship be-
tween TL and unit dominance: dominant unit mean TL 8.84
kb 1.76 and nonengrafting unit mean 10.3 kb 1.81, P¼ .77.
Serial measurements of TL over time (from trans-
plantation day to 1 year) demonstrated an overall decrease in
TL of 3.04 kb  .16. Only 1 patient with complete unit
dominance demonstrated TL maintenance after trans-
plantation, with a mean percentage TL gain of 11.5% (indi-
cated with asterisk, Figure 1A). The 10 remaining patients
with complete unit dominance demonstrated a TL decrease
with an overall mean percentage loss of -32.7%  3.5. TL also
shortened in the 2 remaining patients with sustained coen-
graftment of both units (Figure 1C). When we evaluated the
changes in TL over time in the patients’ peripheral blood, the
initial average TL was 8.19 kb  1.41 at day 28 and 6.49 kb 
.96 at 1 year after transplantation or last follow-up (P ¼ .09),
demonstrating an overall trend toward telomere shortening.DISCUSSION
We demonstrate for the ﬁrst time that despite the wide
variation in TL in publically banked CB units at the time of
transplantation, TL does not appear to inﬂuence unit domi-
nance in double-unit CBT. Because of the small number of
patients, we were not able to investigate whether TL in-
ﬂuences the speed and success of donor-derived neutrophil
engraftment. Such analyses would require large numbers of
patients and multivariate analysis controlling for the infused
viable CD34þ cell dose of the dominant unit, an established
critical determinant of engraftment after double-unit CBT
[7]. A further signiﬁcant ﬁnding is that only 1 patient of 13
showed TL stabilization. This patient likely had persistent
telomerase activity, as has been reported in CB for approxi-
mately 4 to 5 months after birth [3]. TL stabilization has also
been observed in a small minority of autologous HSC re-
cipients who underwent transplantation for the treatment of
multiple myeloma (M.A.S. Moore, unpublished data, 2013).
It shouldbeacknowledgedthat theday28sample inpatient
2 (Figure1B)andall time-points frombothpatients inFigure1C
had combinations of both units  a host component, limiting
the TL assessment of the individual CB units. Nonetheless,
taken together, the data from our analysis would suggest thatall but 1 patient demonstrated an overall decrease in TL as
would be expected after multiple rounds of cell division.
A signiﬁcant and unavoidable inherent limitation of this
studywas that true HSCwere not able to be puriﬁed from the
patient’s graft to speciﬁcally evaluate the TL in this cell
subpopulation. The number of HSC required to perform such
an analysis would be prohibitive, and this questionwill likely
never be able to be addressed. Additionally, telomerase ac-
tivity from HSC isolated from the patient in serial samples
after transplantation was also not able to be evaluated.
Nonetheless, we propose that evaluation of CB MNC is an
acceptable surrogate for HSC TL assessment, as has been
suggested in analysis of adult peripheral blood.
Taken together, we postulate that telomerase activitymay
be high but insufﬁcient to compensate for the robust HSC
expansion that is necessary for sustained engraftment and
the high proliferation of more differentiated progenitors.
Moreover, based on our preliminary data, we suggest that in
the majority of adult CBT recipients, a transition from a fetal-
neonatal to adult HSC is made characterized by lower telo-
merase activity and asymmetric division in vivo. When this
transition would naturally occur in normal human develop-
ment, however, is unknown and it would be of interest to
compare the natural history of TL in normal children versus
patients who underwent transplantation with CB. Follow-up
of adult CBT recipients who are healthy long-term survivors
would suggest this observation has no clinical relevance.
However, the clinical implications of telomere shortening in
CBT recipients and the comparison of CBT recipients with
those of adult donor allografts require further investigation.
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